A refined prediction model for survival in hepatocellular carcinoma patients treated with transarterial chemoembolization.

ABSTRACT:

Background/aims

Transarterial chemoembolization (TACE) is widely performed as a major treatment for hepatocellular carcinoma (HCC) patients, and there is a need to stratify patients for whom the most benefit from the treatment. This study aimed to develop a refined prediction model for overall survival (OS) in patients undergoing TACE as a first-line treatment in a large cohort and validate its performance.

Methods

A total of 2,632 patients with HCC of Barcelona Clinic Liver Cancer stage A or B who underwent TACE between 2008 and 2017 were enrolled. The patients were randomly assigned to a training cohort (n = 1,304) or a validation cohort (n = 1,328). Independent predictors of OS were used to develop a prediction model.

Results

The median age of patients in the entir

SUBMITTER: Lee HL 

PROVIDER: S-EPMC11007070 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature